Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1930 1
1932 1
1935 1
1937 1
1940 1
1941 1
1946 4
1947 1
1948 1
1949 1
1950 4
1951 1
1952 1
1954 1
1956 3
1957 5
1958 5
1959 4
1960 11
1961 3
1962 17
1963 14
1964 6
1965 15
1966 9
1967 14
1968 12
1969 10
1970 22
1971 16
1972 27
1973 28
1974 18
1975 19
1976 30
1977 21
1978 22
1979 19
1980 29
1981 33
1982 35
1983 29
1984 28
1985 41
1986 37
1987 52
1988 43
1989 45
1990 41
1991 48
1992 36
1993 51
1994 49
1995 50
1996 28
1997 46
1998 44
1999 52
2000 48
2001 44
2002 45
2003 29
2004 59
2005 50
2006 81
2007 80
2008 88
2009 90
2010 96
2011 91
2012 101
2013 129
2014 128
2015 151
2016 163
2017 136
2018 153
2019 151
2020 148
2021 170
2022 156
2023 146
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

3,432 results

Results by year

Filters applied: . Clear all
Page 1
Asthma.
Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Porsbjerg C, et al. Among authors: shaw d. Lancet. 2023 Mar 11;401(10379):858-873. doi: 10.1016/S0140-6736(22)02125-0. Epub 2023 Jan 19. Lancet. 2023. PMID: 36682372 Review.
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.
Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Jones J, et al. Among authors: shaw d. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870. N Engl J Med. 2023. PMID: 37530822 Clinical Trial.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schönherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB. Subbiah V, et al. Among authors: shaw de. Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475. Cancer Discov. 2023. PMID: 37270847 Free PMC article.
Erratum.
Shaw D. Shaw D. Aerosp Med Hum Perform. 2022 Sep 1;93(9):709. doi: 10.3357/AMHP.9309.Erratum. Aerosp Med Hum Perform. 2022. PMID: 36224727
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, Bulku A, DiPietro L, Fridrich C, Frost A, Giordanetto F, Hamilton EP, Harris K, Holliday M, Hunter TL, Iskandar A, Ji Y, Larivée A, LaRochelle JR, Lescarbeau A, Llambi F, Lormil B, Mader MM, Mar BG, Martin I, McLean TH, Michelsen K, Pechersky Y, Puente-Poushnejad E, Raynor K, Rogala D, Samadani R, Schram AM, Shortsleeves K, Swaminathan S, Tajmir S, Tan G, Tang Y, Valverde R, Wehrenberg B, Wilbur J, Williams BR, Zeng H, Zhang H, Walters WP, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Fraser JS, Fortin PD, Kipp DR. Varkaris A, et al. Among authors: shaw de. Cancer Discov. 2024 Feb 8;14(2):240-257. doi: 10.1158/2159-8290.CD-23-0944. Cancer Discov. 2024. PMID: 37916956 Free PMC article.
Authors' reply.
Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, Das A, Bisherwal K, Shaw D, Vasani R. Verma SB, et al. Among authors: shaw d. Indian J Dermatol Venereol Leprol. 2022 Nov-Dec;88(6):798-799. doi: 10.25259/IJDVL_1090_2021. Indian J Dermatol Venereol Leprol. 2022. PMID: 35138058 Free article. No abstract available.
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
Bartels U, Onar-Thomas A, Patel SK, Shaw D, Fangusaro J, Dhall G, Souweidane M, Bhatia A, Embry L, Trask CL, Murphy ES, MacDonald S, Wu S, Boyett JM, Leary S, Fouladi M, Gajjar A, Khatua S. Bartels U, et al. Among authors: shaw d. Neuro Oncol. 2022 Jun 1;24(6):974-983. doi: 10.1093/neuonc/noab270. Neuro Oncol. 2022. PMID: 34850169 Free PMC article. Clinical Trial.
3,432 results